Daniel E Spratt (@DrSpratticus) ranks #5 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 75 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: PROTEUS, PANTHA, ASCENDERT. CMS Open Payments lists $9,495 in 2025 general payments.
At a Glance
- 7 posts naming a trial in 2026
- 4 trials discussed by name
- GU Cancer: US #5, Global #8 · 75 physicians engaged
- Leading physician voice: #3 of 56 physicians on PROTEUS
- CMS Open Payments lists $9,495 in 2025 general payments.
This Month
What Daniel E Spratt has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Daniel E Spratt
Physicians who reposted Daniel E Spratt’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #5 | #8 | 75 | 116 | Full ranking |
Trials Daniel E Spratt Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| PROTEUS | 4 | #3 of 56 | May 31, 2026 |
| PANTHA | 1 | — | Mar 1, 2026 |
| ASCENDERT | 1 | — | Feb 26, 2026 |
| BRCAAway | 1 | #4 of 5 | Feb 26, 2026 |
Daniel E Spratt on PROTEUS
#ASCO26 The PROTEUS trial results are now online...buckle up as we wait to see the full presentation. This is going to be a trial that is likely highly controversial until the full results are published. Some may call this a homerun, others may call this the largest negative trial @ASCO 2026. Up to you to interpret! @urotoday @EricTopol @DrChoueiri @neerajaiims @ASCO @US_FDA @NCCN @myESMO @ASTRO_org @PCF_Science @declangmurphy @mcuban
8/n #ASCO26 The largest issue with the PROTEUS trial is that it changed its primary endpoint of MFS by conventional imaging to now allow PET imaging. Without understanding the breakdown, they potentially changed it to effectively EFS. We all know that adding ADT/ARPI should suppress PSA more effectively, which will delay BCR, which will improve EFS....but it has morbidity and does it help men experience life better or longer? @US_FDA
9/n #ASCO26 In PROTEUS it is likely only a subset of MFS events were called based on PET, but unknown at this time breakdown: -EFS: HR 0.71 (0.63-0.80); fairly modest relative benefit for a BCR driven endpoint; that is far above the STE to translate to an OS benefit. -MFS (includes PET): HR 0.80 (0.67-0.96) exceeds the EFS STE as well as the 95%CI exceeds the ICECaP STE for conventional imaging MFS (ie STE is 0.81 and CI is 0.96). End of the day the effect size is too small to confidently state it would later improve OS.
Daniel E Spratt on PANTHA
@Larvol @ASCO @DrRishabhOnco I didn’t discuss Pantha…can you show me when I did?
Daniel E Spratt on ASCENDERT
#GU26 Up next: 15 yr OS from the ASCENDE-RT RCT of external beam boost versus brachytherapy boost in localized prostate cancer - Prospective f/u ended at 10 years, but death certificates and other data sources were looked beyond 10 years (so high risk of attribution bias, no further DM data presented, etc). -Median age of patients at 15yrs are 82yo; 54% of patietns have died (younger and healthier cohort than most RT trials) -No difference in OS (p=0.8) on UVA or MVA. -PCSM better in brachy arm, which means that OCM was worse in brachy arm (numerically). Could all simply be attribution bias. @HimanshuNagarMD @seanmmcbride @AmarUKishan @ASCO
Daniel E Spratt on BRCAAway
#GU26 Updated OS data from BRCAAway: Phase 2 trial of abi, olaparib, or abi + olaparib in 1st-line mCRPC with DNA repair defects (unfortunately includes ATM) @MahaHussain presents results. No significant OS differences but numerical differences observed. Small trial with ~20 pts/arm, thus OS data uninterpretable but signal finding. Combo moderately toxic w/ >20% grade 3+ toxicity. Objective response 22% w/ abi vs 33% w/ combo. PFS curves in combo arm separate early but converge ~4 years...is upfront better than sequential? TBD @ASCO @urotoday
Daniel E Spratt’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
2/n #ASCO26 The design. Peri-operative ADT (12m) + RP vs Peri-operative ADT+Apa (12m) + RP Robustly blinded, placebo controlled. Some may criticize that the SOC is not RP+ADT, but simply RP, but others may state this raises the bar to show benefit of apalutamide. @WallisCJD @HimanshuNagarMD @ChapinMD @CaPsurvivorship @wandering_gu
#ASCO26 Unfortunate interpretation Matt. Morbidity of early SRT is not even remotely comparable to 1 year of ADT/ARPI. Yet by 5 years still 25% got RT (quadruplet therapy). Patients want to avoid ADT whenever possible. For patients the real Q is do you want triplet therapy and still have have 80% chance of not being disease free at 5 years? Likely near 95% by 10 yrs. This is very disappointing so few men are cured with RP despite doublet systemic tx. MFS benefit of apalutamide in Luminal B patients way larger with SRT than in Proteus.
Industry Payments
CMS Open Payments · 2025 general payments
$9,495 across 7 payments